Latest News

Friday, September 22, 2017 | Personnel/Company News, PracticalDermatology.com, Product Launches and Updates

Dr. Michael H. Gold Joins AIVITA Scientific Advisory Board

Nashville dermatologist Michael H. Gold, MD, has joined AIVITA Biomedical’s Scientific Advisory Board. His addition comes as AIVITA prepares to launch its upcoming ROOT OF SKINTM line of reju…

Read the full story

Friday, September 22, 2017 | PracticalDermatology.com, Product Launches and Updates

Dove: Women’s Shower Routines May Do More Harm Than Good

Close to 80 percent of dermatologists believe women often focus on facial skincare, but neglect body skincare, according to new research from Dove. What’s more, 69 percent of dermatologists r…

Read the full story

Thursday, September 21, 2017 | PracticalDermatology.com, Product Launches and Updates

New Data: Aclaris’ A-101 40% Safely Banishes Facial SK Lesions

Good news for Aclaris. New data suggest that their drug candidate A-101 40 percent may be an appealing option to remove seborrheic keratosis (SK) lesions in highly visible areas, such a…

Read the full story

Wednesday, September 20, 2017 | PracticalDermatology.com, Product Launches and Updates, Sun Pharmaceutical Industries Ltd

New Label Reflects Sustained Response for Sun Pharma’s Odomzo in BCC

Sun Pharma’s new Odomzo® (Sonidegib) label incorporates long-term data showing sustained duration of response of 26 months in treatment of locally advanced basal cell carcinoma. Odom…

Read the full story

Wednesday, September 20, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Research and Publications

Two-Year Data: TREMFYA™ (guselkumab) Achieves Consistent Rates of Skin Clearance in Moderate to Severe Plaque Psoriasis

New longer-term data from the open-label extension of the VOYAGE 1 trial demonstrate consistent rates of skin clearance with TREMFYA™ treatment through week 100 among patients with moderate…

Read the full story

Tuesday, September 19, 2017 | Personnel/Company News, PracticalDermatology.com

Eva Genel Named Director of Research and Development, Skincare at Silk Therapeutics

Eva Genel is the new Director of Research and Development, Skincare at Silk Therapeutics Inc., a specialty biomaterials company. In this new role, Genel's key responsibilities include designing…

Read the full story

Monday, September 18, 2017 | PracticalDermatology.com, Product Launches and Updates, Skinceuticals

SkinCeuticals Launches Two New Cosmeceutical Cleansers

SkinCeuticals is launching two new cleansers: Replenishing Cleanser and Smoothing Cleanser. What’s more, the original cleansers are all being repacked and reformulated. The new Replenishing C…

Read the full story

Monday, September 18, 2017 | PracticalDermatology.com, Research and Publications

U.K Survey Reveals Eczema Treatment Knowledge Gap

Two thirds of UK eczema patients don’t understand that bacteria play a crucial role in their condition despite studies showing that Staphylococcus aureus is present on the skin in of more than 7…

Read the full story

Monday, September 18, 2017 | PracticalDermatology.com, Regeneron, Sanofi

EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe AD

Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to…

Read the full story

Friday, September 15, 2017 | Personnel/Company News, PracticalDermatology.com, Galderma

Happy 70th Cetaphil!

Cetaphil is turning 70! To celebrate this milestone birthday, which takes place on Sept. 19, Cetaphil will launch a series of initiatives including: A 70-hour flash sale across retail partner…

Read the full story

Thursday, September 14, 2017 | PracticalDermatology.com, Research and Publications, JAK inhibitors

Lilly’s Baricitinib Performs Well in Phase 2 AD Study

Lilly’s experimental JAK inhibitor Baricitinib in combination with a mid-potency topical corticosteroid (TCS) significantly improved the signs and symptoms of moderate-to-severe atopic dermatiti…

Read the full story

Wednesday, September 13, 2017 | PracticalDermatology.com, Product Launches and Updates, Research and Publications

Vanda's Tradipitant Improves Itch and Disease Severity in AD Patients

Vanda Pharmaceuticals Inc.’s tradipitant improved the intensity of the worst itch patients experienced, as well as atopic dermatitis (AD) disease severity,  according to results from an eig…

Read the full story

Wednesday, September 13, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Novartis

Five-Year Data Show Sustained Efficacy, Safety for Cosentyx

Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase …

Read the full story

Wednesday, September 13, 2017 | PracticalDermatology.com, Research and Publications, Psoriasis

IPC, Others Call for Creation of Worldwide Psoriasis Database

A new report calls for the creation of a web-based Global Psoriasis Atlas (GPA) database that will document the prevalence and incidence of psoriasis worldwide. The report, entitled "Global St…

Read the full story

Tuesday, September 12, 2017 | Personnel/Company News, PracticalDermatology.com, Product Launches and Updates, Allergan , SkinMedica, Zeltiq

Allergan Adds Coolsculpting, Other Bells and Whistles to Brilliant Distinctions® Patient Loyalty Program

Allergan is launching the next generation of its U.S.-based Brilliant Distinctions® program. The new offering incorporates digital innovation to enhance the consumer experience and drive increa…

Read the full story
Load More